OR WAIT null SECS
Pure MHC and Catalent sign an agreement to develop RL21A using Catalent's GPEx technology.
Pure MHC, a provider of MHC-based diagnostics and therapeutics, and Catalent have signed a product-development agreement under which Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody, an anticancer agent, and engineer a cell line to express the antibody using Catalent’s GPExO, technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A. MHC (major histocompatibility complex) is a group of genes that code proteins found on the surface of cells that help the immune system recognize foreign substances.
Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets.